Pre-market futures are up this morning, though somewhat muted from levels prior to economic reports out this morning on unemployment claims. We also see a full compliment of Q1 earnings reports ahead of today’s opening bell, with another couple “Mag 7” companies due to report after today’s close.Jobless Claims Jump Higher Last WeekFor months, we’ve been talking in this space about the steadiness and resiliency of weekly unemployment claims. While other metrics on the economy and employment have begun to sho ...

Group 1 - CVS Health Corporation announced its Q1 2025 earnings, with a positive market response reflected in a share price increase of over 7% [2] - The company provides detailed financial models and research focused on the pharmaceutical, biotech, and healthcare sectors [2] - The investing group Haggerston BioHealth, led by a biotech consultant, offers insights into product sales, forecasts, and market analysis for major pharmaceutical companies [2]

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The news team covers medium and small-cap markets, as well as blue-chip companies, commodities, and broader investment stories [3] - Proactive focuses on sectors such as biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Group 2 - Proactive is committed to adopting technology to enhance workflows and content production [4] - The company utilizes automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]

CVS Health (CVS) reported $94.59 billion in revenue for the quarter ended March 2025, representing a year-over-year increase of 7%. EPS of $2.25 for the same period compares to $1.31 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $92.95 billion, representing a surprise of +1.76%. The company delivered an EPS surprise of +31.58%, with the consensus EPS estimate being $1.71.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street ...

CVS Health Corporation (CVS) posted adjusted earnings per share (EPS) of $2.25 in the first quarter of 2025, up 71.8% year over year. The metric also topped the Zacks Consensus Estimate by 34.7%. The adjusted EPS figure considers certain asset amortization costs, loss on assets held for sale and other adjustments. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)On a reported basis, the company’s GAAP earnings were $1.41 per share compared with 88 cents in the prior-year period.CVS’ ...

CVS表示，其保险子公司Aetna将在2026年全面终止在ACA市场的运营。Aetna于2018年被CVS以780亿 美元收购。公司指出，退出的主要原因是该业务板块在2025年保险年度预计将面临亏损，本季度在个体 医保产品线上计提了4.48亿美元的保费亏损准备金。 尽管如此，CVS健康保险业务一季度的表现仍有亮点。该业务所在的"健康福利"板块收入同比增长约 8%，达348亿美元，高于市场预期的332亿美元。其中，受益于Medicare医保计划表现超出预期，该板 块的医疗赔付率从去年同期的90.4%降至87.3%，显示盈利能力改善。 智通财经APP获悉，周四，美国医疗健康巨头西维斯健康(CVS.US)股价走高，截至发稿，该股涨超 7%，报71.56美元。该公司宣布将于2026年退出个人健康保险市场，也就是"奥巴马医保"计划(ACA个体 医保市场)。 在药房和消费者健康板块，CVS的表现同样强劲。该板块季度收入达到319亿美元，同比增长约11%， 高于市场预期。公司在季度内共处理了约4.355亿份处方订单，同比增长4.3%。 整体来看，该公司季度实现总营收946亿美元，超出市场预期12亿美元；调整后每股收益同比大 ...

CVS Health (CVS) came out with quarterly earnings of $2.25 per share, beating the Zacks Consensus Estimate of $1.71 per share. This compares to earnings of $1.31 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 31.58%. A quarter ago, it was expected that this drugstore chain and pharmacy benefits manager would post earnings of $0.89 per share when it actually produced earnings of $1.19, delivering a surprise of 33.71%.Over the ...

Financial Data and Key Metrics Changes - The company reported first quarter adjusted earnings per share of $2.25 and adjusted operating income of $4.6 billion, with revenues of nearly $95 billion, reflecting a 7% increase year-over-year [4][23] - Full year 2025 adjusted EPS guidance was increased to a range of $6 to $6.2, up from the previous range of $5.75 to $6 [4][35] - Cash flows from operations for the quarter were approximately $4.6 billion, allowing for an increase in full year cash flow guidance [23][34] Business Line Data and Key Metrics Changes - The Healthcare Benefits segment generated nearly $35 billion in revenue, an 8% increase year-over-year, driven by growth in the Medicare business [24] - Adjusted operating income for the Healthcare Benefits segment was approximately $2 billion, an increase of over $1.2 billion from the prior year [25] - The Health Services segment reported revenues of over $43 billion, an increase of nearly 8% year-over-year, primarily driven by pharmacy drug mix and specialty growth [30] - The Pharmacy and Consumer Wellness segment generated revenues of nearly $32 billion, an increase of over 11% year-over-year, with same-store pharmacy sales growing nearly 18% [32][33] Market Data and Key Metrics Changes - Medical membership was approximately 27.1 million, flat sequentially, with a decline of about 300,000 members expected in the second quarter due to the expiration of the premium grace period for individual exchange members [24] - The company processed over 464 million pharmacy claims during the quarter, with total pharmacy services membership at approximately 88 million [31] Company Strategy and Development Direction - The company aims to become America's most trusted health care company by improving outcomes, expanding access, and addressing rising health care costs [6][7] - A focus on digital capabilities is being emphasized to enhance customer engagement and improve health care experiences [8][9] - The company plans to exit the individual exchange business in 2026, allowing for a focus on more profitable areas such as Medicare, commercial, and Medicaid [20][21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate a challenging environment, highlighting strong execution and operational stability [4][41] - There are early signs of stabilization in medical cost trends, particularly in the Medicare segment, although elevated trends remain a concern [27][56] - The company is closely monitoring the impact of tariffs and potential changes in consumer sentiment towards vaccines [80] Other Important Information - The company announced a partnership with Novo Nordisk to increase access to Wegovy, a weight management medication, at a more affordable price [14][63] - The company is committed to supporting individual exchange members until the end of the year, despite plans to exit the market [49] Q&A Session Summary Question: Insights on Medicare Advantage trends - Management acknowledged early trends in individual and Part D Medicare Advantage, with some pressure in Group Medicare Advantage, indicating a cautious but optimistic outlook [41][46] Question: Details on the relationship with Novo for Wegovy - The partnership aims to increase access to Wegovy for members, with a focus on affordability and improved outcomes through Caremark [58][63] Question: Clarification on prior year revenue adjustments - Management explained that prior year development occurred across all business lines, with the majority being favorable in Medicare, impacting the overall guidance positively [68][72]

Financial Data and Key Metrics Changes - The company reported first quarter adjusted earnings per share of $2.25 and adjusted operating income of $4.6 billion, with revenues of nearly $95 billion, reflecting a 7% increase year-over-year [5][26] - Full year 2025 adjusted EPS guidance was increased to a range of $6 to $6.2, up from the previous range of $5.75 to $6 [5][37] - Cash flows from operations for the quarter were approximately $4.6 billion, allowing for an increase in full year cash flow guidance [26][36] Business Line Data and Key Metrics Changes - The Healthcare Benefits segment generated nearly $35 billion in revenue, an 8% increase year-over-year, driven by growth in the Medicare business [27] - Adjusted operating income for the Healthcare Benefits segment was approximately $2 billion, an increase of over $1.2 billion from the prior year [28] - The Health Services segment reported revenues of over $43 billion, an increase of nearly 8% year-over-year, primarily driven by pharmacy drug mix and specialty growth [32] - The Pharmacy and Consumer Wellness segment generated revenues of nearly $32 billion, an increase of over 11% year-over-year, driven by increased prescription volume [34] Market Data and Key Metrics Changes - Medical membership was approximately 27.1 million, flat sequentially, with a decline of about 300,000 members expected in the second quarter due to premium grace period expirations [27] - The company processed over 464 million pharmacy claims during the quarter, with total pharmacy services membership at approximately 88 million [33] - Retail pharmacy script share grew to approximately 27.6%, an increase of about 70 basis points from the same period last year [35] Company Strategy and Development Direction - The company aims to become America's most trusted health care company, focusing on improving outcomes, expanding access, and addressing rising health care costs [9][24] - A strategic exit from the individual exchange business is planned for 2026, allowing the company to concentrate on areas with stronger capabilities, such as Medicare and Medicaid [23][24] - The partnership with Novo Nordisk aims to increase access to Wegovy at a more affordable price, demonstrating the company's commitment to driving competition and affordability in the market [17][66] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate a challenging and volatile environment, highlighting solid performance across all business segments [5][22] - Elevated medical cost trends are being monitored closely, with early signs of stabilization noted in some areas [30][58] - The company remains cautious about the outlook for certain products and segments, particularly in Medicare Advantage and individual exchanges [40] Other Important Information - The company has appointed new leadership, including a new CFO and CMO, to strengthen its management team [7] - The company is actively managing its portfolio to ensure sustainable earnings and competitive viability [22] Q&A Session Summary Question: Insights on Medicare Advantage trends - Management noted early signs of stabilization in Medicare Advantage, with a focus on operational rigor and cost management [44][49] Question: Impact of the Wegovy announcement on guidance - The Wegovy announcement does not impact current guidance, as savings will benefit customers directly [77][79] Question: Potential tariff impacts on the business - The company is monitoring tariff impacts closely, particularly in the pharmaceutical supply chain, but does not expect significant effects on front store items sourced domestically [81][83] Question: Pressure observed at Oak Street - Early signs of pressure in medical cost trends at Oak Street Health were noted, with ongoing monitoring planned [85][88]

First Quarter 2025 May 1, 2025 Earnings Conference Call J. David Joyner President and Chief Executive Officer Thomas F. Cowhey Executive Vice President and Chief Financial Officer 1 ©2025 CVS Health and/or one of its affiliates. Confidential and proprietary. Cautionary Statement concerning forward-looking statements This presentation includes forward-looking statements. The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by or on behalf of CVS Heal ...